Patents by Inventor Michael Ehrenstein

Michael Ehrenstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250306020
    Abstract: The invention relates to the use of IgA2 antibodies, in particular IgA2 anti-dsDNA antibodies, as a biomarker. The antibodies may be use as a biomarker for autoimmune disease, such as SLE. The antibodies may also be used to identify a subject with an autoimmune disease who is likely to benefit from treatment with an agent which targets B-cell Activating Factor (BAFF).
    Type: Application
    Filed: May 9, 2023
    Publication date: October 2, 2025
    Inventors: Michael Ehrenstein, Muhammad Shipa
  • Patent number: 10376518
    Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 13, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
  • Publication number: 20160030439
    Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 4, 2016
    Inventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
  • Publication number: 20100196402
    Abstract: The present invention relates to a method for predicting the response of a patient to treatment with an anti-TNF? therapy, in particular an anti-TNF? antibody, the method comprising: (a) providing an in vitro sample of T cells from the patient; (b) exposing said T cells to an anti-TNF? therapy; and (c) determining whether regulatory T cells are induced in said sample of T cells wherein the induction of regulatory T cells indicates that the patient is likely to respond to treatment with said anti-TNF? therapy.
    Type: Application
    Filed: May 20, 2008
    Publication date: August 5, 2010
    Applicant: UCL BUSINES PLC
    Inventors: Michael Ehrenstein, Claudia Mauri